SLC6A1 Connect: Comprehensive Company Profile

Background

Mission and Vision

SLC6A1 Connect is a parent-led, non-profit patient advocacy organization dedicated to improving the lives of children and families affected by SLC6A1-related disorders. The organization focuses on raising awareness and funding pioneering scientific research to ensure that every individual with SLC6A1 has access to effective treatments and, ultimately, a cure.

Primary Area of Focus

The organization centers on SLC6A1-related disorders, a rare neurological condition characterized by epilepsy, movement and speech disorders, intellectual disability, and a range of behavioral and psychiatric challenges. SLC6A1 Connect aims to accelerate research and therapies, support affected families, advocate for increased awareness, and fundraise to advance scientific breakthroughs.

Industry Significance

As a dedicated patient advocacy group, SLC6A1 Connect plays a pivotal role in the rare disease community by uniting families, clinicians, scientists, and industry partners. Its efforts have led to significant advancements in research and treatment options for SLC6A1-related disorders, highlighting the organization's impact on the field.

Key Strategic Focus

Core Objectives

• Accelerate Research & Therapies: Fund innovative scientific research aimed at developing disease-modifying treatments, including gene therapy and other novel approaches.

• Support Families: Provide guidance and resources to families affected by SLC6A1-related disorders, ensuring they have access to necessary information and support systems.

• Advocate & Raise Awareness: Increase visibility of SLC6A1 in the broader epilepsy, autism, and rare disease communities through partnerships and media engagement.

• Power Progress Through Fundraising: Raise critical funds to support research initiatives and move promising ideas toward clinical trials.

Specific Areas of Specialization

SLC6A1 Connect specializes in the following areas:

• Gene Therapy Research: Developing gene replacement therapies to address the underlying genetic causes of SLC6A1-related disorders.

• Preclinical and Translational Studies: Supporting studies that bridge the gap between laboratory research and clinical application, facilitating faster access to treatments.

• Family Support and Resources: Offering practical resources, support groups, and community connections to assist families in managing the challenges associated with SLC6A1-related disorders.

Key Technologies Utilized

The organization collaborates with academic and research institutions to utilize advanced technologies, including:

• Gene Editing Tools: Employing CRISPR and other gene-editing technologies to develop potential gene therapies.

• Cellular and Organoid Models: Creating patient-specific cellular and organoid models to test FDA-approved drugs and potential therapies.

Primary Markets or Conditions Targeted

SLC6A1 Connect focuses on:

• SLC6A1-Related Epileptic Encephalopathy: A rare genetic disorder characterized by early-onset seizures and intellectual disability.

• Neurodevelopmental Disorders: Conditions affecting the development of the nervous system, leading to cognitive and motor impairments.

Financials and Funding

Funding History

SLC6A1 Connect has raised over $7 million to support its mission, funding various research initiatives and supporting families affected by SLC6A1-related disorders.

Recent Funding Rounds

The organization has engaged in multiple fundraising activities, including events like golf tournaments, dinners, and media campaigns, to support its research and advocacy efforts.

Notable Investors

As a non-profit organization, SLC6A1 Connect's funding primarily comes from individual donors, families, and community supporters rather than traditional investors.

Intended Utilization of Capital

The funds raised are allocated towards:

• Research Initiatives: Advancing gene therapy research and preclinical studies.

• Family Support Programs: Providing resources and support to families affected by SLC6A1-related disorders.

• Advocacy and Awareness Campaigns: Increasing visibility and understanding of SLC6A1 in the broader medical and public communities.

Pipeline Development

Key Pipeline Candidates

SLC6A1 Connect is actively involved in the development of gene replacement therapies for SLC6A1-related disorders. Collaborations with institutions like the University of Texas Southwestern have led to the creation of transgenic mouse models to test potential therapeutics, including antisense oligonucleotide therapies.

Stages of Clinical Trials or Product Development

The organization has progressed from preclinical studies to initiating clinical trials for gene replacement therapies. In September 2025, Amber Freed's son became the first patient to receive a gene replacement therapy for SLC6A1-related neurodevelopmental disorder.

Target Conditions

The primary focus is on SLC6A1-related epileptic encephalopathy and other neurodevelopmental disorders associated with the SLC6A1 gene.

Relevant Timelines for Anticipated Milestones

The organization aims to advance gene replacement therapies from preclinical stages to clinical trials, with ongoing efforts to secure FDA approval and expand treatment options for affected individuals.

Technological Platform and Innovation

Proprietary Technologies

SLC6A1 Connect collaborates with research institutions to develop proprietary gene replacement therapies and utilizes patient-specific cellular and organoid models for drug testing.

Significant Scientific Methods

• Gene Editing: Employing CRISPR and other gene-editing technologies to develop potential gene therapies.

• Cellular and Organoid Models: Creating patient-specific models to test FDA-approved drugs and potential therapies.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, the organization collaborates with academic and research institutions that may utilize AI in their research efforts.

Leadership Team

Amber N. Freed – Founder and CEO

Amber Freed founded SLC6A1 Connect after her son, Maxwell, was diagnosed with an SLC6A1 variant. With a background in equity analysis, she left her career to dedicate her efforts to finding a cure for SLC6A1-related disorders.

Kimberly Fry – Vice President

Kimberly Fry joined the leadership team in late 2019 after her son, Charles Fry, was diagnosed with an SLC6A1-related disorder. With over 12 years of marketing and event expertise, she serves as the Director of Marketing and Events at ProActive Solutions.

Competitor Profile

Market Insights and Dynamics

The rare disease market, particularly for SLC6A1-related disorders, is characterized by a small patient population, leading to challenges in research funding and treatment development. However, advancements in gene therapy and increased awareness are creating opportunities for innovation and collaboration.

Competitor Analysis

SLC6A1 Connect collaborates with other patient advocacy groups, such as the SynGAP Research Fund and Cure GABA-A Variants, to accelerate research and treatment development. This collaborative approach enhances the organization's impact and fosters a supportive community for affected families.

Strategic Collaborations and Partnerships

SLC6A1 Connect has established partnerships with various organizations to strengthen its mission:

• COMBINEDBrain: A non-profit consortium of 25 patient-advocacy groups, including SLC6A1 Connect, aiming to speed clinical trial readiness for severe cognitive disorders by pooling resources and collaborating across member disorders.

• Simons Searchlight: An international research program building a natural history database and resource network for rare genetic neurodevelopmental disorders, including SLC6A1-related syndrome.

Operational Insights

SLC6A1 Connect's collaborative approach with other patient advocacy groups and research institutions enhances its operational effectiveness. By pooling resources and expertise, the organization accelerates research and treatment development for SLC6A1-related disorders.